Non-Invasive Prenatal Testing (NIPT) Market Size, Share & Trends Report

Non-Invasive Prenatal Testing (NIPT) Market Size, Share & Trends Analysis Report, By Gestation Period (0-12 weeks, 13-24 weeks, 25-36 weeks), By Risk (High & Average Risk, Low Risk) And Segment Forecasts, 2018 - 2025

  • Published Date: Mar, 2018
  • Base Year for Estimate: 2015
  • Report ID: GVR-1-68038-310-2
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 103

Industry Insights

The global non-invasive prenatal testing market size was estimated at USD 1.19 billion in 2015. Advantages associated with the use of these tests such as leading to a significant reduction in the number of expensive and risky invasive amniocentesis and Chorionic Villus Sampling (CVS) procedures are estimated to improve the volumetric capabilities of the market at a global level which would directly translate into the growth in revenue for this market at a larger level.

Evolution of prenatal testing, in the form of non-invasive tests that can serve as an intermediate step between screening and invasive tests in order to determine the probability of fetal abnormality is expected to drive growth in the reproductive genetics industry over the forecast period. 

UK non-invasive prenatal testing market

The growth in this market is attributed to the accelerated customer adoption of NIPT procedures coupled with the expansion in the distribution services of the operating entities which enables them to materially capture the potential NIPT opportunity. In addition to this, coverage expansion by the payers into average-risk pregnancies over the forecast period in order to realize savings on amniocentesis and the treatment of Down's Syndrome is anticipated to enhance the penetration of non-invasive prenatal testing products, consequently influencing revenue generation in this vertical.

Presence of companies, such as Anthem and Blue Shield of California that have endorsed DNA-based NIPT screening for trisomy 13, 18, and 21, is expected to impact the adoption rate of these tests, thereby resulting to growth in the revenue generation. Moreover, there is less delineation between high and average risk, which is expected to enhance volumetric capabilities.

The development of NIPT for genetic conditions is a major commercial interest owing to high demand in the disease segments such as Down Syndrome. China is expected to remain a significant opportunity for non-invasive prenatal screening, with nearly 16 million annual births out of which around 900, 000 fall under the category of high-risk pregnancies.

Gestation Period Insights

Highly accurate results are gained by the virtue of screening in the first trimester i.e. around 95%. However, the detection rates in the second trimester remain to be 80%. Several companies have focused on the analysis of cffDNA in a sample of maternal blood collected in the first trimester to develop a more accurate and reliable NIPT.

However, the gestation period of 13-24 weeks is expected to witness a substantial growth due to the rise in the number of market participants that are engaged in the development of more accurate and reliable NIPT for the analysis of cffDNA in a sample of maternal blood collected in the first trimester.

Risk Type Insights

The market is well penetrated with respect to high risk, however, there are few payers that do not have favorable medical coverage decisions for average risk testing. Average risk guideline inclusion in the reimbursement for the NIPT procedures is expected to serve as a forthcoming catalyst for the growth of this vertical in the coming years.

Factors that attribute the large share include presence of the favorable payor reimbursement in this segment coupled with the rising awareness pertaining to the prevention of occurrence of chromosomal anomalies such as Downs Syndrome. The available products in the market provide sensitivity within the range of 99.0% to 99.9% for the detection of the Down’s syndrome.

Regional Insights

North America accounted for the major share in 2015. Factors attributive include capital intensive, high R&D investment markets and their inter-related development dependencies that are integral to the progress. Furthermore, due to the availability of technologically advanced healthcare research framework, the development of WGS in the region is also expected to serve as a critical factor for the growth of North America NIPT market throughout the forecast period.

Global non-invasive prenatal testing market

The presence of significant developments by China and Japan for technological integration of NGS methodologies, and the development of healthcare, R&D and clinical development frameworks of emerging economies such as India and Australia have poised the Asia Pacific NIPT market to witness lucrative opportunities o growth throughout the forecast period.

Non-invasive Prenatal Testing Market Share Insights

Some of the major participants include Sequenom, Roche (Ariosa Diagnostics); Natera, LabCorp, BGI Genomics; Quest Diagnostics, Illumina, and Berry Genomics. These participants are engaged in the development and licensing of the software and cloud distribution model to enhance technology transfer. The companies are focusing on gaining the characteristics of both rapid growth equipment companies and emerging lab companies in order to gain a larger share of the revenue.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 to 2016

Forecast period

2016 - 2025

Market representation

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

The U.S., Canada, Germany, The U.K., China, Japan, Brazil, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global non-invasive prenatal testing market report on the basis of gestation period, risk type, and region:

  • Gestation Period Outlook (Revenue, USD Million, 2014 - 2025)

    • 0-12 weeks

    • 13-24 weeks

    • 25-36 weeks

  • Risk-type Outlook (Revenue, USD Million, 2014 - 2025)

    • High & Average Risk

    • Low Risk

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • The U.K.

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa

Pricing & Purchase Options

Service Guarantee

  • Quality assurance

    Insured Buying

    This report has a service guarantee. We stand by our report quality.

  • Information security


    We are in compliance with GDPR & CCPR norms. All interactions are confidential.

  • grand view research PCI DSS complaint grand view research gdpr verified
  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities